摘要
目的探讨表皮生长因子受体(EGFR)在胸腺瘤中的表达及其意义。方法免疫组化SP法检测63例患者胸腺瘤(胸腺瘤组)和20例胸腺增生(胸腺增生组)组织中EGFR的表达,分析胸腺瘤EGFR表达与其病理分级及临床分期的相关性。结果胸腺瘤组EGFR表达阳性率高于胸腺增生组(52.4%vs.20.0%)(P<0.05)。直径>6cm的胸腺瘤EGFR表达阳性率高于直径≤6cm的胸腺瘤(P<0.05)。胸腺瘤EGFR表达水平与病理分级及临床分期呈正相关。胸腺瘤的预后和临床分期相关。结论 EGFR可能在胸腺瘤的进展和预后中发挥重要作用。EGFR可能成为胸腺瘤新的治疗靶点和预后的标志物。
Objective To investigate the expression and clinical significance of epidermal growth factor receptor（EGFR） in thymoma. Methods The expression of EGFR was detected in 63 patients with thymoma（group A） and 20 patients with thymic hyperplasia（group B） by immunohistochemistry.The correlation between EGFR levels in thymoma and the factors determining the prognosis and progression of thymoma was analyzed. Results The positive expression rate of EGFR was significantly higher in group A than that in group B（52.4% vs.20.0%）（P0.05）,which was higher in the thymoma 6 cm in diameter than that in those ≤6 cm（P0.05）.The expression of EGFR in thymoma was positively correlated with pathological classification and clinical stage.The prognosis of patients with thymoma was related to clinical stage. Conclusion EGFR may play an important role in the progression and prognosis in the patients with thymoma and could be a novel therapeutic target and prognostic marker for thymoma.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第9期1035-1037,共3页
Jiangsu Medical Journal
关键词
表皮生长因子受体
胸腺瘤
Epidermal growth factor receptor
Thymoma
